Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation

Diagnostic Pathology

Volumn 11, Issue 1, 2016, Pages

  Bae, Ja Seong ^a   Kim, Yourha ^a,b   Jeon, Sora ^a,b   Kim, Se Hee ^b   Kim, Tae Jung ^b   Lee, Sohee ^a   Kim, Min Hee ^a   Lim, Dong Jun ^a   Lee, Youn Soo ^a   Jung, Chan Kwon ^b  

^a The Catholic University of Korea   (South Korea)

^b The Catholic University of Korea   (South Korea)

Author keywords

Anaplastic lymphoma kinase; BRAF V600E; Iodine 131; Telomerase reverse transcriptase; Thyroid cancer

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; B RAF KINASE; BRAF PROTEIN, HUMAN; PROTEIN TYROSINE KINASE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT; TELOMERASE; TERT PROTEIN, HUMAN; TUMOR MARKER;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA; CARCINOMA, MEDULLARY; CELL DIFFERENTIATION; DECISION SUPPORT SYSTEM; DNA MUTATIONAL ANALYSIS; ENZYMOLOGY; ETHNOLOGY; EVALUATION STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FREQUENCY; GENE REARRANGEMENT; GENETIC PREDISPOSITION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; META ANALYSIS; MIDDLE AGED; MOLECULAR DIAGNOSIS; MUTATION; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROMOTER REGION; RETROSPECTIVE STUDY; SECONDARY; SOUTH KOREA; THYROID NEOPLASMS; TREATMENT OUTCOME;

ADENOCARCINOMA, FOLLICULAR; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS, TUMOR; CARCINOMA; CARCINOMA, MEDULLARY; CELL DIFFERENTIATION; DECISION SUPPORT TECHNIQUES; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENE REARRANGEMENT; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; RADIOPHARMACEUTICALS; RECEPTOR PROTEIN-TYROSINE KINASES; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; TELOMERASE; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 84958102918     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/s13000-016-0458-6     Document Type: Article

References (49)

1. Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3):184-99. doi: 10.1038/nrc3431.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. doi: 10.3322/caac.20107.
3. Toniato A, Boschin I, Casara D, Mazzarotto R, Rubello D, Pelizzo M. Papillary thyroid carcinoma: factors influencing recurrence and survival. Ann Surg Oncol. 2008;15(5):1518-22. doi: 10.1245/s10434-008-9859-4.
4. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97(5):418-28.
5. Tuttle RM, Ball DW, Byrd D, Dilawari RA, Doherty GM, Duh QY, et al. Thyroid carcinoma. J Natl Compr Canc Netw. 2010;8(11):1228-74.
6. Melck AL, Yip L, Carty SE. The utility of BRAF testing in the management of papillary thyroid cancer. Oncologist. 2010;15(12):1285-93. doi: 10.1634/theoncologist.2010-0156.
7. Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, et al. The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. Cancer. 2012;118(7):1764-73. doi: 10.1002/cncr.26500.
8. Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013;381(9871):1058-69. doi: 10.1016/S0140-6736(13)60109-9.
9. Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf). 2005;63(5):588-93. doi: 10.1111/j.1365-2265.2005.02389.x.
10. Fukushima T, Suzuki S, Mashiko M, Ohtake T, Endo Y, Takebayashi Y, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 2003;22(41):6455-7. doi: 10.1038/sj.onc.1206739.
11. Cho U, Oh WJ, Bae JS, Lee S, Lee YS, Park GS, et al. Clinicopathological features of rare BRAF mutations in Korean thyroid cancer patients. J Korean Med Sci. 2014;29(8):1054-60. doi: 10.3346/jkms.2014.29.8.1054.
12. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12(2):245-62. doi: 10.1677/erc.1.0978.
13. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90(12):6373-9. doi: 10.1210/jc.2005-0987.
14. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-54. doi: 10.1038/nature00766.
15. Nam JK, Jung CK, Song BJ, Lim DJ, Chae BJ, Lee NS, et al. Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer? Am J Surg. 2012;203(4):436-41. doi: 10.1016/j.amjsurg.2011.02.013.
16. Ito Y, Yoshida H, Maruo R, Morita S, Takano T, Hirokawa M, et al. BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients. Endocr J. 2009;56(1):89-97.
17. Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, et al. Frequency of TERT promoter mutations in human cancers. Nat Commun. 2013;4:2185. doi: 10.1038/ncomms3185.
18. Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014;32(25):2718-26. doi: 10.1200/JCO.2014.55.5094.
19. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339(6122):959-61. doi: 10.1126/science.1230062.
20. Liu X, Wu G, Shan Y, Hartmann C, von Deimling A, Xing M. Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle. 2013;12(10):1637-8. doi: 10.4161/cc.24662.
21. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 2013;20(4):603-10. doi: 10.1530/erc-13-0210.
22. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz Jr LA, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013;110(15):6021-6. doi: 10.1073/pnas.1303607110.
23. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339(6122):957-9. doi: 10.1126/science.1229259.
24. Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, et al. TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. J Clin Endocrinol Metab. 2014;99(5):E754-65. doi: 10.1210/jc.2013-3734.
25. Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J, et al. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene. 2014;33(42):4978-84. doi: 10.1038/onc.2013.446.
26. Chou A, Fraser S, Toon CW, Clarkson A, Sioson L, Farzin M, et al. A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma. Am J Surg Pathol. 2015;39(5):652-9. doi: 10.1097/pas.0000000000000368.
27. Demeure MJ, Aziz M, Rosenberg R, Gurley SD, Bussey KJ, Carpten JD. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target. World J Surg. 2014;38(6):1296-305. doi: 10.1007/s00268-014-2485-3.
28. Kelly LM, Barila G, Liu P, Evdokimova VN, Trivedi S, Panebianco F, et al. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci U S A. 2014;111(11):4233-8. doi: 10.1073/pnas.1321937111.
29. Park G, Kim TH, Lee HO, Lim JA, Won JK, Min HS, et al. Standard immunohistochemistry efficiently screens for anaplastic lymphoma kinase rearrangements in differentiated thyroid cancer. Endocr Relat Cancer. 2015;22(1):55-63. doi: 10.1530/erc-14-0467.
30. Perot G, Soubeyran I, Ribeiro A, Bonhomme B, Savagner F, Boutet-Bouzamondo N, et al. Identification of a recurrent STRN/ALK fusion in thyroid carcinomas. PLoS One. 2014;9(1):e87170. doi: 10.1371/journal.pone.0087170.
31. McFadden DG, Dias-Santagata D, Sadow PM, Lynch KD, Lubitz C, Donovan SE, et al. Identification of oncogenic mutations and gene fusions in the follicular variant of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2014;99(11):E2457-62. doi: 10.1210/jc.2014-2611.
32. Network TCGAR. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676-90. doi: 10.1016/j.cell.2014.09.050.
33. Oh WJ, Lee YS, Cho U, Bae JS, Lee S, Kim MH, et al. Classic papillary thyroid carcinoma with tall cell features and tall cell variant have similar clinicopathologic features. Korean J Pathol. 2014;48(3):201-8. doi: 10.4132/KoreanJPathol.2014.48.3.201.
34. Jung CK, Im SY, Kang YJ, Lee H, Jung ES, Kang CS, et al. Mutational patterns and novel mutations of the BRAF gene in a large cohort of Korean patients with papillary thyroid carcinoma. Thyroid. 2012;22(8):791-7. doi: 10.1089/thy.2011.0123.
35. Liu T, Brown TC, Juhlin CC, Andreasson A, Wang N, Backdahl M, et al. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors. Endocr Relat Cancer. 2014;21(3):427-34. doi: 10.1530/erc-14-0016.
36. Sabra MM, Dominguez JM, Grewal RK, Larson SM, Ghossein RA, Tuttle RM, et al. Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. J Clin Endocrinol Metab. 2013;98(5):E829-36. doi: 10.1210/jc.2012-3933.
37. Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. J Clin Endocrinol Metab. 2013;98(9):E1562-6. doi: 10.1210/jc.2013-2383.
38. Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, et al. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab. 2014;99(6):E1130-6. doi: 10.1210/jc.2013-4048.
39. Dettmer MS, Schmitt A, Steinert H, Capper D, Moch H, Komminoth P, et al. Tall cell papillary thyroid carcinoma: new diagnostic criteria and mutations in BRAF and TERT. Endocr Relat Cancer. 2015;22(3):419-29. doi: 10.1530/erc-15-0057.
40. Gandolfi G, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A, Sancisi V. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. Eur J Endocrinol. 2015;172(4):403-13. doi: 10.1530/eje-14-0837.
41. Muzza M, Colombo C, Rossi S, Tosi D, Cirello V, Perrino M, et al. Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization. Mol Cell Endocrinol. 2015;399:288-95. doi: 10.1016/j.mce.2014.10.019.
42. Qasem E, Murugan AK, Al-Hindi H, Xing M, Almohanna M, Alswailem M, et al. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population. Endocr Relat Cancer. 2015;22(6):901-8. doi: 10.1530/erc-15-0396.
43. Shi X, Liu R, Qu S, Zhu G, Bishop J, Liu X, et al. Association of TERT promoter mutation 1,295,228 C > T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer. J Clin Endocrinol Metab. 2015;100(4):E632-7. doi: 10.1210/jc.2014-3606.
44. Yu XM, Schneider DF, Leverson G, Chen H, Sippel RS. Follicular variant of papillary thyroid carcinoma is a unique clinical entity: a population-based study of 10,740 cases. Thyroid. 2013;23(10):1263-8. doi: 10.1089/thy.2012.0453.
45. Hong AR, Lim JA, Kim TH, Choi HS, Yoo WS, Min HS, et al. The frequency and clinical implications of the BRAF(V600E) mutation in papillary thyroid cancer patients in Korea over the past two decades. Endocrinol Metab (Seoul). 2014;29(4):505-13. doi: 10.3803/EnM.2014.29.4.505.
46. Pillai S, Gopalan V, Smith RA, Lam AK. Diffuse sclerosing variant of papillary thyroid carcinoma--an update of its clinicopathological features and molecular biology. Crit Rev Oncol Hematol. 2015;94(1):64-73. doi: 10.1016/j.critrevonc.2014.12.001.
47. Zhang Z, Liu D, Murugan AK, Liu Z, Xing M. Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer. Endocr Relat Cancer. 2014;21(2):161-73. doi: 10.1530/erc-13-0399.
48. Yang K, Wang H, Liang Z, Liang J, Li F, Lin Y. BRAFV600E mutation associated with non-radioiodine-avid status in distant metastatic papillary thyroid carcinoma. Clin Nucl Med. 2014;39(8):675-9. doi: 10.1097/rlu.0000000000000498.
49. Huang DS, Wang Z, He XJ, Diplas BH, Yang R, Killela PJ, et al. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation. Eur J Cancer. 2015;51(8):969-76. doi: 10.1016/j.ejca.2015.03.010.